Latest Bisphosphonate Stories
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
CAMBRIDGE, Mass., Aug.
Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018...
Non-adherent women up to six times more likely to experience a fracture WOONSOCKET, R.I., May 11 /PRNewswire/ -- Data released today by CVS Caremark (NYSE: CVS) indicates that 87 percent of women 18 years and older with osteoporosis, who were taking a drug therapy to treat the disease, did not experience a fracture during the two-year study period.
Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates.
Researchers at the Armed Forces Radiobiology Research Institute in Bethesda, Maryland, reported Sunday that two compounds in a class of bone-strengthening drugs known as bisphosphonates may protect people exposed to radiation from developing leukemia -- a common long-term side effect of radiation exposure.
New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.
ADA creates brochures with National Osteoporosis Foundation CHICAGO, March 9 /PRNewswire-USNewswire/ -- Dental patients who have been alarmed or confused by recent news reports about how osteoporosis medications might affect their oral health now have a brochure to help them separate fact from fiction.
ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition.
Researchers at the University Of Southern California, School Of Dentistry release results of clinical data that links oral bisphosphonates to increased jaw necrosis.
- A transitional zone between two communities containing the characteristic species of each.